Technical Analysis for VVUS - VIVUS, Inc.

Grade Last Price % Change Price Change
grade B 4.15 0.73% 0.03
VVUS closed up 0.73 percent on Friday, September 13, 2019, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical VVUS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.73%
Wide Bands Range Expansion 0.48%
20 DMA Support Bullish 0.73%
1,2,3 Pullback Bullish Bullish Swing Setup 0.73%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.73%
Wide Bands Range Expansion 0.73%
MACD Bearish Signal Line Cross Bearish 2.72%

Older signals for VVUS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Medicine Chemistry Health Biopharmaceutical Diabetes Obesity Diabetes Mellitus Hypertension Psychiatric Diagnosis Sleep Disorders Obstructive Sleep Apnea Sleep Apnea Erectile Dysfunction Treatment Of Obesity Chronic Weight Management Female Sexual Dysfunction High Cholesterol
Is VVUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.8
52 Week Low 2.15
Average Volume 122,924
200-Day Moving Average 3.8052
50-Day Moving Average 3.6753
20-Day Moving Average 4.059
10-Day Moving Average 4.104
Average True Range 0.2546
ADX 35.42
+DI 22.6353
-DI 11.8634
Chandelier Exit (Long, 3 ATRs ) 3.9862
Chandelier Exit (Short, 3 ATRs ) 3.9638
Upper Bollinger Band 4.6449
Lower Bollinger Band 3.4731
Percent B (%b) 0.58
BandWidth 28.86918
MACD Line 0.1409
MACD Signal Line 0.1606
MACD Histogram -0.0197
Fundamentals Value
Market Cap 439.13 Million
Num Shares 106 Million
EPS 0.31
Price-to-Earnings (P/E) Ratio 13.39
Price-to-Sales 0.55
Price-to-Book 13.45
PEG Ratio -2.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.31
Resistance 3 (R3) 4.31 4.25 4.28
Resistance 2 (R2) 4.25 4.21 4.25 4.27
Resistance 1 (R1) 4.20 4.19 4.23 4.20 4.27
Pivot Point 4.15 4.15 4.16 4.15 4.15
Support 1 (S1) 4.10 4.11 4.12 4.10 4.03
Support 2 (S2) 4.04 4.08 4.04 4.03
Support 3 (S3) 3.99 4.04 4.02
Support 4 (S4) 3.99